Predict your next investment

Venture Capital
FINANCE | Investment Firms & Funds
sunstone.eu

See what CB Insights has to offer

Investments

192

Portfolio Exits

37

Funds

19

Partners & Customers

1

About Sunstone Capital

Sunstone Capital is an early-stage Life Science and Technology venture capital company investing in European start-up companies with strong potential to achieve global success in their markets. Sunstone's portfolio consists of companies in the areas of communication technologies, components, software & digital media, medical technologies, pharmaceuticals, diagnostics and biotechnology.

Sunstone Capital Headquarters Location

Lautrupsgade 7 2nd Floor

Copenhagen, 2100,

Denmark

+45 2012 6000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sunstone Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Sunstone Capital in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Sunstone Capital Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sunstone Capital Rank

Latest Sunstone Capital News

Major Shareholder Announcement

Jun 15, 2021

16/2021Company Registration No. 32266355 Copenhagen, Denmark, June 15 , 2021 - Orphazyme A/S (ORPHA.CO; ORPH) ("the Company"), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Sunstone Life Science Ventures A/S and Sunstone Life Science Ventures Fund II K/S, that as of June 11, 2021, Sunstone Life Science Ventures Fund II K/S holds less than 5% of the Company's share capital and that Sunstone Life Science Ventures A/S as of June 11, 2021, controls less than 5% of the voting rights in the Company. Sunstone Life Science Ventures Fund II K/S is managed by its general partner Sunstone LSV General Partner II ApS. Sunstone Life Science Ventures A/S control all voting rights of Sunstone LSV General Partner II ApS. For additional information, please contact Orphazyme A/S Anders Vadsholt, CFO                +45 28 98 90 55 About Orphazyme A/SOrphazyme is a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases. The company is harnessing amplification of heat shock proteins (or HSPs) to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction, including lysosomal storage diseases. Arimoclomol, the company's lead candidate, is in clinical development for Niemann-Pick disease type C (NPC) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme's shares are listed on Nasdaq U.S. (ORPH) and Nasdaq Copenhagen (ORPHA.CO). About arimoclomolArimoclomol is an investigational drug candidate that amplifies the production of heat shock proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is administered orally, and has now been studied in 10 phase 1, four phase 2 and three pivotal phase 2/3 trials. Arimoclomol is in clinical development for NPC and Gaucher disease. Arimoclomol has received orphan drug designation (ODD) for NPC in the US and EU. Arimoclomol has received fast-track designation (FTD) from the U.S. Food and Drug Administration (FDA) for NPC. In addition, arimoclomol has received breakthrough therapy designation (BTD) and rare-pediatric disease designation (RPDD) from the FDA for NPC. Arimoclomol is an investigational treatment and has not been approved by the FDA. Forward-looking statementThis company announcement may contain certain forward-looking statements, including in respect of the expected PDUFA action date of June 17, 2021 for arimoclomol for the treatment of NPC, the potential U.S. approval of arimoclomol in June and the opinion from the Committee for Medicinal Products for Human Use (CHMP) later this year. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could", and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Attachment

Sunstone Capital Investments

192 Investments

Sunstone Capital has made 192 investments. Their latest investment was in TargED Biopharmaceuticals as part of their Series A on February 2, 2022.

CBI Logo

Sunstone Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/22/2022

Series A

TargED Biopharmaceuticals

$44.23M

Yes

5

8/25/2021

Series B

Cardior Pharmaceuticals

$76M

Yes

7

3/24/2021

Series B

Step Pharma

$41.37M

Yes

2

1/13/2021

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

12/15/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/22/2022

8/25/2021

3/24/2021

1/13/2021

12/15/2020

Round

Series A

Series B

Series B

Series B - II

Series B

Company

TargED Biopharmaceuticals

Cardior Pharmaceuticals

Step Pharma

Subscribe to see more

Subscribe to see more

Amount

$44.23M

$76M

$41.37M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

7

2

10

10

Sunstone Capital Portfolio Exits

37 Portfolio Exits

Sunstone Capital has 37 portfolio exits. Their latest portfolio exit was Blackwood Seven on April 25, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/25/2022

Acquired

$99M

3

3/1/2022

Acquired

$99M

3

11/11/2021

Acquired

$99M

10

11/5/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

8/2/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/25/2022

3/1/2022

11/11/2021

11/5/2021

8/2/2021

Exit

Acquired

Acquired

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

3

10

10

10

Sunstone Capital Fund History

19 Fund Histories

Sunstone Capital has 19 funds, including Sunstone Fixed Income Fund III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/13/2020

Sunstone Fixed Income Fund III

$8M

1

2/7/2019

Life Science Ventures Fund IV

Early-Stage Venture Capital

Open

$90.86M

4

11/3/2017

Sunstone Technology Fund IV

Early-Stage Venture Capital

Closed

$130.12M

2

11/3/2017

Sunstone Progression Alpha

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2012

Sunstone Life Science Ventures III

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

7/13/2020

2/7/2019

11/3/2017

11/3/2017

12/31/2012

Fund

Sunstone Fixed Income Fund III

Life Science Ventures Fund IV

Sunstone Technology Fund IV

Sunstone Progression Alpha

Sunstone Life Science Ventures III

Fund Type

Early-Stage Venture Capital

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Open

Closed

Subscribe to see more

Subscribe to see more

Amount

$8M

$90.86M

$130.12M

$99M

$99M

Sources

1

4

2

10

10

Sunstone Capital Partners & Customers

1 Partners and customers

Sunstone Capital has 1 strategic partners and customers. Sunstone Capital recently partnered with Zymenex on August 8, 2013.

Date

Type

Business Partner

Country

News Snippet

Sources

8/26/2013

Partner

Denmark

PE HUB » Sunstone Capital Exits Zymenex

Patient focus and high quality research in all aspects of the development process are the basis for the company 's success , '' says Sten Verland , Chairman of the Board in Zymenex and partner with Sunstone Capital .

1

Date

8/26/2013

Type

Partner

Business Partner

Country

Denmark

News Snippet

PE HUB » Sunstone Capital Exits Zymenex

Patient focus and high quality research in all aspects of the development process are the basis for the company 's success , '' says Sten Verland , Chairman of the Board in Zymenex and partner with Sunstone Capital .

Sources

1

Sunstone Capital Team

6 Team Members

Sunstone Capital has 6 team members, including current Founder, Founding Partner, Peter Benson.

Name

Work History

Title

Status

Peter Benson

Vækstfonden, Pfizer, and Unilever

Founder, Founding Partner

Current

Sten Verland

Synarc, Taconic Biosciences, University of Copenhagen, and University of California, Berkeley

Founding Partner, General Partner

Current

Dr. Søren Lemonius

Managing Partner

Current

Claus Andersson

General Partner

Current

Max Niederhofer

Accel, Qwerly, and Atlas Venture

General Partner

Former

Name

Peter Benson

Sten Verland

Dr. Søren Lemonius

Claus Andersson

Max Niederhofer

Work History

Vækstfonden, Pfizer, and Unilever

Synarc, Taconic Biosciences, University of Copenhagen, and University of California, Berkeley

Accel, Qwerly, and Atlas Venture

Title

Founder, Founding Partner

Founding Partner, General Partner

Managing Partner

General Partner

General Partner

Status

Current

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.